Literature DB >> 28988893

Radiation therapy of synchronous bilateral breast carcinoma (SBBC) using multiple techniques.

Sung Jin Kim1, Mi Jo Lee2, Seon Min Youn3.   

Abstract

The purpose of this study was to establish intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) treatment plans for synchronous bilateral breast cancer (SBBC) and to compare those plans with the previous treatment plans using 3D conformal radiation therapy (3DCRT). The differences among the treatments were also statistically compared regarding dosimetry distribution and treatment efficiency. The research was conducted with 10 SBBC patients. The study established IMRT (12 fields with a single isocenter) and VMAT (2 partial arcs with a single isocenter) treatment plans for SBBC patients and then compared those plans with 3DCRT (8 fields with multiple isocenters). The plans were evaluated based on a dose-volume histogram analysis. For planning target volumes (PTVs), the mean doses and the values of V95%, V105%, conformity index, and homogeneity index were reported. For the organs at risk, the analysis included the mean dose, maximum dose, and VXGy, depending on the organs (lungs, heart, and liver). To objectively evaluate the efficiency of the treatment plans, each plan's beam times, treatment times (including set-up time), and monitor units were compared. Tukey test and one-way analysis of variance were used to compare the PTV and organs at risk values of the 3 techniques. Additionally, the independent-samples t-test was used to compare the 2 techniques (IMRT and VMAT) based on the values of Rt. PTV and Lt. PTV (p < 0.05). For PTV dose distribution, IMRT showed increases of approximately 1.2% in Dmean and of approximately 5.7% in V95% dose distribution compared with 3DCRT. In comparison to VMAT, 3DCRT showed about 3.0% higher dose distribution in Dmean and V95%. IMRT was the best in terms of conformity index and homogeneity index (p < 0.05), whereas 3DCRT and VMAT did not significantly differ from each other. In terms of dose distribution on lungs, heart, and liver, the percentage of volume at high doses such as V30Gy and V40Gy was approximately 70% lower for IMRT and approximately 40% lower for VMAT than for 3DCRT. For distribution volumes of low doses such as V5% and V10%, that for 3DCRT was approximately 60% smaller than for IMRT and approximately 70% smaller than for VMAT. Comparison between IMRT and VMAT showed that the IMRT was superior in all distribution factors. VMAT showed better treatment efficiency than 3DCRT or IMRT. Among the SBBC radiotherapy treatment plans, IMRT was superior to 3DCRT and VMAT in terms of PTV dose distribution, whereas VMAT showed the most outstanding treatment efficiency.
Copyright © 2017 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3DCRT; IMRT; Synchronous bilateral breast cancer; VMAT

Mesh:

Year:  2017        PMID: 28988893     DOI: 10.1016/j.meddos.2017.08.003

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  9 in total

1.  Skin and lung toxicity in synchronous bilateral breast cancer treated with volumetric-modulated arc radiotherapy: a mono-institutional experience.

Authors:  M Valli; S Cima; D Gaudino; R Cartolari; L Deantonio; M Frapolli; D Daniele; G A Pesce; F Martucci; N C Azinwi; D Bosetti; S Presilla; A Richetti
Journal:  Clin Transl Oncol       Date:  2019-03-14       Impact factor: 3.405

2.  Intensity Modulated Proton Therapy for Bilateral Breast or Chest Wall and Comprehensive Nodal Irradiation for Synchronous Bilateral Breast Cancer: Initial Clinical Experience and Dosimetric Comparison.

Authors:  Allison E Garda; Ashley E Hunzeker; Ann K Michel; Sayeh Fattahi; Satomi Shiraishi; Nicholas B Remmes; Heather L Schultz; W Scott Harmsen; Dean A Shumway; Elizabeth S Yan; Sean S Park; Robert W Mutter; Kimberly S Corbin
Journal:  Adv Radiat Oncol       Date:  2022-01-24

3.  Techniques for Treating Bilateral Breast Cancer Patients Using Pencil Beam Scanning Technology.

Authors:  Melissa A L Vyfhuis; Mingyao Zhu; Benjamin Agyepong; Elizabeth M Nichols
Journal:  Int J Part Ther       Date:  2019-09-24

4.  Evaluation of fixed-jaw IMRT and tangential partial-VMAT radiotherapy plans for synchronous bilateral breast cancer irradiation based on a dosimetric study.

Authors:  Jiang-Hua Huang; Xiu-Xiu Wu; Xiao Lin; Jun-Tian Shi; Yu-Jia Ma; Song Duan; Xiao-Bo Huang
Journal:  J Appl Clin Med Phys       Date:  2019-09-04       Impact factor: 2.102

5.  Synchronous bilateral breast cancer treated with a 3-week hypofractionated radiotherapy schedule: clinical and dosimetric outcomes.

Authors:  J Gadea; I Ortiz; R Roncero; I Alastuey; F Mestre; N Aymar; J E Maturana; C Garcia; L Mateu; J Pardo
Journal:  Clin Transl Oncol       Date:  2021-04-08       Impact factor: 3.405

6.  Dosimetric comparison of normal breathing and deep inspiration breath hold technique for synchronous bilateral breast cancer using 6MV flattened beam and flattening filter free beam.

Authors:  Suresh Tamilarasu; Madeswaran Saminathan
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

7.  Hypofractionated Hybrid Radiotherapy Techniques for Synchronous Bilateral Breast Cancer.

Authors:  Karunakaran Balaji; Velayudham Ramasubramanian
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

8.  Evaluation of the dosimetric and radiobiological parameters in four radiotherapy regimens for synchronous bilateral breast cancer.

Authors:  Sang-Won Kang; Seonghee Kang; Boram Lee; Changhoon Song; Keun-Yong Eom; Bum-Sup Jang; In Ah Kim; Jae-Sung Kim; Woong Cho; Dong-Suk Shin; Jin-Young Kim; Jin-Beom Chung
Journal:  J Appl Clin Med Phys       Date:  2022-06-21       Impact factor: 2.243

9.  Efficacy, safety, and feasibility of volumetric modulated arc therapy for synchronous bilateral breast cancer management.

Authors:  Stanislas Quesada; Pascal Fenoglietto; Sophie Gourgou; Claire Lemanski; Roxana Draghici; Norbert Ailleres; Jessica Prunaretty; David Azria; Céline Bourgier
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.